Pharmacologic treatments for covid-19 patients
Analyses are updated every Friday
Treatment comparisons
Create and download your forest plots with the most up-to-date data here Forest plots
Access the forest plots for the 269 treatment comparisons .
General characteristics of primary studies
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT02735707, NCT04505774, NCT04359277, NCT04372589 Goligher E, N Engl J Med, 2021 Full text Full text Commentary |
Mixed | Therapeutic heparin | Prophylactic anticoagulant | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 393 centers in Australia, Brazil, Canada, Ireland, Mexico, Netherlands, New Zealand, Saudi Arabia, UK, USA | N=1207 |
Some concerns Details |
|
| IRCT20201003048904N2 Abbasi F, 2021 Full text Commentary Commentary |
Public/non profit | Sitagliptin | Standard care | RCT | Patients with suspected or confirmed COVID-19 (unclear severity) admitted to 2 centers in Iran. | N=263 | N/A | |
| Spironolactone | Standard care | |||||||
| Sitagliptin+Spironolactone | Standard care | |||||||
| IRCT20200328046886N1 Abbaspour Kasgari H, J Antimicrob Chemoth, 2020 Full text Commentary |
Public/non profit | Sofosbuvir-Daclatasvir+Ribavirin | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to a single center in Iran. | N=48 |
Some concerns Details |
|
| ISRCTN21085622 Abbass S, 2021 Full text Commentary |
Private | Sofosbuvir+Daclatasvir | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Egypt | N=120 |
Some concerns Details |
|
| Sofosbuvir+Daclatasvir | Sofosbuvir+Ravidasvir | |||||||
| Sofosbuvir+Ravidasvir | Standard care | |||||||
| NCT04353336 Abd-Elsalam S, Am J Trop Med Hyg, 2020 Full text Commentary |
Public/non profit | Hydroxychloroquine | Standard care | RCT | Patients with COVID-19 (mild-severe) admitted to three university hospitals in Egypt. | N=194 |
Some concerns Details |
|
| NCT04447534 Abd-Elsalam S, Biol Trace Elem Res, 2020 Full text Commentary |
Hydroxychloroquine+Zinc | Hydroxychloroquine | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 3 centers in Egypt | N=191 |
Some concerns Details |
||
| NCT04403555 Abd-Elsalam S, J Med Virol, 2021 Full text Commentary |
Not reported/unclear | Ivermectin | Standard care | RCT | Patients with confirmed COVID-19 admitted to 2 centers in Egypt | N=164 |
Some concerns Details |
|
| NCT04753619 Abdulamir A, Ann Med Surg, 2021 Full text Full text Commentary Commentary |
No specific funding | Niclosamide | Standard care | RCT | Outpatients and inpatients with confirmed COVID-19 (mild-moderate-severe) admitted or treated by 2 centers in Iraq | N=150 |
Some concerns Details |
|
| NCT04315948; EudraCT Ader F, DisCoVeRy, Clin Microbiol Infect, 2021 Full text Commentary ; Commentary |
Mixed | Lopinavir-Ritonavir | Lopinavir-Ritonavir+Interferon beta-1a | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 32 centers in France and Luxembourg | N=603 |
Some concerns Details |
|
| Lopinavir-Ritonavir | Hydroxychloroquine | |||||||
| Lopinavir-Ritonavir | Standard care | |||||||
| Lopinavir-Ritonavir+Interferon beta-1a | Hydroxychloroquine | |||||||
| Lopinavir-Ritonavir+Interferon beta-1a | Standard care | |||||||
| Hydroxychloroquine | Standard care | |||||||
| NCT04315948, EudraCT2020-000936-23 Ader F, Lancet Infect Dis, 2021 Full text Full text Commentary |
Public/non profit | Remdesivir | Standard care | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 48 centers in France (39), Belgium (3), Portugal (2), Austria (3), and Luxembourg (1). | N=857 |
Some concerns Details |
|
| CTRI/2020/04/024775 PLACID Agarwal A, BMJ, 2020 Full text Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (mild to severe) admitted to 39 centers in India. | N=464 |
Some concerns Details |
|
| NCT04407130 Ahmed S, 2020 Full text Commentary |
Private | Ivermectin+Doxycycline | Placebo | RCT | Patients with confirmed COVID-19 (mild) admitted to hospital in Bangladesh. | N=72 |
Some concerns Details |
|
| Ivermectin+Doxycycline | Ivermectin | |||||||
| Ivermectin | Placebo | |||||||
| NCT04350684 Alavi Darazam I (2), Int Immunopharmacol, 2021 Full text Commentary |
No specific funding | Lopinavir/ritonavir + hydroxychloroquine + interferon-Beta1a + umifenovir | Lopinavir/ritonavir + hydroxychloroquine + interferon Beta-1a | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. | N=101 |
Some concerns Details |
|
| IRCT20200328046882N1 Alavi-moghaddam M, SSRN, 2021 Full text Commentary |
Public/non profit | Sofosbuvir | Lopinavir-Ritonavir+Interferon beta-1a | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Iran | N=57 |
Some concerns Details |
|
| NCT04521309 Ali S, EClinicalMedicine , 2021 Full text 00206-6/fulltext Commentary |
Public/non profit | Hyperimmune anti-COVID-19 Intravenous Immunoglobulin | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Pakistan | N=50 |
Some concerns Details |
|
| NCT04356534 AlQahtani M, Sci Rep, 2021 Full text Commentary Commentary |
Public/non profit | Standard care | Convalescent plasma | RCT | Patients with confirmed COVID-19 (severe) admitted to 2 centers in Bahrain | N=40 |
Some concerns Details |
|
| NCT04573153 Altay O, Adv. Sci., 2021 Full text Full text Commentary |
Private | Combined metabolic cofactor supplementation | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated at a single center in Turkey | N=93 |
Some concerns Details |
|
| EudraCT 2020–001236–10 Aman J, Lancet Respir Med, 2021 Full text Commentary |
Public/non profit | Imatinib | Placebo | RCT | Patients with confirmed COVID-19 (severe) admitted to 13 centers in the Netherlands. | N=400 |
Some concerns Details |
|
| NCT04329923 Amaravadi R, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Hydroxychloroquine | Placebo | RCT | Outpatients with confirmed COVID-19 (symptomatic, mild ) treated by a single center in USA | N=34 |
Some concerns Details |
|
| IRCT20170207032444N3 Amra B, Research Square, 2021 Full text Commentary Commentary |
Public/non profit | Thalidomide | Standard care | RCT | Patients with suspected or confirmed COVID-19 (severe) admitted to a single center in Iran | N=60 |
High Details |
|
| NCT04504032 Ananworanich J, Clin Infect Dis, 2021 Full text Commentary Commentary |
Public/non profit | Rivaroxaban | Placebo | RCT | Outpatients with confirmed COVID-19 (mild, symptomatic) treated at 13 centers and one virtual site in the USA. | N=497 |
Some concerns Details |
|
| NCT02735707 Angus DC, JAMA, 2020 Full text Commentary |
Public/non profit | Fixed-dose hydrocortisone | Standard care | RCT | Patients with COVID-19 (severe-critical) admitted to 121 centers in 8 countries | N=251 |
Some concerns Details |
|
| IRCT20200317046797N4 Ansarin K, BioImpacts, 2020 Full text Commentary |
Public/non profit | Bromhexine | Standard care | RCT | Patients with COVID-19 (unclear severity) at a single center in Iran | N=78 |
Some concerns Details |
|
| NCT02735707 Arabi Y, 2021 Full text Commentary |
Mixed | Lopinavir-Ritonavir | Standard care | RCT | Patients with suspected or confirmed COVID-19 (critical) admitted to a multiple centers in Australia, Canada, France, Germany, Ireland, Netherlands, New Zealand, Portugal, Saudi Arabia, UK, and USA | N=726 |
Some concerns Details |
|
| Lopinavir-Ritonavir | Hydroxychloroquine | |||||||
| Lopinavir-Ritonavir | Hydroxychloroquine+Lopinavir+Ritonavir | |||||||
| Hydroxychloroquine | Hydroxychloroquine+Lopinavir+Ritonavir | |||||||
| Hydroxychloroquine | Standard care | |||||||
| Hydroxychloroquine+Lopinavir+Ritonavir | Standard care | |||||||
| NCT04412772 ARCHITECTS, Unpublished, 2021 |
Public/non profit | Tocilizumab | Placebo | RCT | Patients with confirmed COVID-19 (critical) admitted to a single center in the USA. | N=21 |
Low Details |
|
| NCT04716569 Aref ZF, Int J Nanomed, 2021 Full text Commentary |
Public/non profit | Ivermectin | Standard care | RCT | Outpatients with confirmed COVID-19 (mild, symptomatic) treated at a single center in Egypt. | N=114 |
Some concerns Details |
|
| NCT04345523 Avendano-Sola C, J Clin Invest, 2021 Full text Full text Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to 27 centers in Spain | N=350 |
Some concerns Details |
|
| ISRCTN40302986 Babalola OE, IVERCOVID, QJM, 2021 Full text Commentary Commentary |
Private | Ivermectin 6mg | Ivermectin 12mg | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in Nigeria | N=62 |
Some concerns Details |
|
| Ivermectin 6mg | Lopinavir-Ritonavir | |||||||
| Ivermectin 12mg | Lopinavir-Ritonavir | |||||||
| NCT04346446 Bajpai M, medRxiv, 2020 Full text Commentary Commentary |
No specific funding | Convalescent plasma | Fresh frozen plasma | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in India | N=31 |
Some concerns Details |
|
| NCT04375098 Balcells M, PLoS Med, 2021 Full text Commentary |
Public/non profit | Early Convalescent plasma | Late Convalescent plasma | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single centre in Chile. | N=58 |
High Details |
|
| NCT04542694 Balykova L, Infektsionnye bolezn, 2020 Full text Commentary |
Private | Favipiravir | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to 5 centers in Russia | N=200 |
Some concerns Details |
|
| NCT04321616 Barratt-Due A, Ann Intern Med, 2021 Full text Full text Commentary |
Mixed | Remdesivir | Standard care | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to 23 centers in Norway | N=101 |
Low Details |
|
| NCT04321616 Barratt-Due A, Ann Intern Med, 2021 Full text Full text Commentary |
Mixed | Hydroxychloroquine | Standard care | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to 23 centers in Norway | N=108 |
Some concerns Details |
|
| NCT04353596 Bauer A, Lancet , 2021 Full text Commentary |
Public/non profit | Continue ARB/ACEI | Discontinue ARB/ACEI | RCT | Outpatients and inpatients with confirmed COVID-19 (mild-severe) admitted to 35 centers in Austria and Germany | N=216 |
Some concerns Details |
|
| NCT04348656 Begin P, medRxiv, 2021 Full text Commentary Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 72 centers in Canada, USA and Brazil. | N=940 |
Some concerns Details |
|
| NCT04280705 Beigel JH, N Engl J Med, 2020 Full text Commentary |
Public/non profit | Remdesivir | Placebo | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 60 centers in 10 countries | N=1062 |
Some concerns Details |
|
| NCT04391127 Beltran-Gonzalez J, 2021 Full text Commentary Commentary |
Public/non profit | Ivermectin | Placebo | RCT | Patients with suspected or confirmed COVID-19 (moderate/severe) admitted to a single center in Mexico | N=106 |
Some concerns Details |
|
| Hydroxychloroquine | Placebo | |||||||
| Ivermectin | Hydroxychloroquine | |||||||
| NCT04344535 Bennett-Guerrero, E, Crit Care Med, 2021 Full text Commentary Commentary |
Private | Convalescent plasma | Standard plasma | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to a single center in USA. | N=74 |
Some concerns Details |
|
| CTRI/2020/12/029855 Bhushan S, Int J Infect Dis, 2021 Full text Commentary |
Private | Pegylated Interferon alpha-2b | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to 20 centers in India. | N=250 |
Some concerns Details |
|
| NCT04429711 Biber A, medRxiv, 2021 Full text Commentary Commentary |
No specific funding | Ivermectin | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated by multiple centers in Israel | N=116 |
Some concerns Details |
|
| NCT04486508 Bikdeli B, Thromb Haemost, 2021 Full text Full text Commentary Commentary Commentary |
Mixed | Standard-Dose prophylactic anticoagulation | Intermediate-Dose prophylactic anticoagulation | RCT | Patients with confirmed COVID-19 (critical) admitted to 10 centers in Iran | N=598 |
Some concerns Details |
|
| NCT04348409 Blum VF, EClinicalMedicine, 2021 Full text Full text Commentary |
Private | Nitazoxanide | Placebo | RCT | Patients with confirmed COVID-19 (mild/moderate) admitted to 6 centers in Brazil. | N=50 |
Some concerns Details |
|
| NCT04323527 Borba MGS, JAMA Netw Open, 2020 Full text Commentary |
Public/non profit | Chloroquine 450mg | Chloroquine 600mg | RCT | Patients with Severe/Critical respiratory syndrome secondary to SARS-CoV-2 infection treated in a single center in Brazil. | N=81 |
Low Details |
Forest plots |
| N/A Borges M, Revista Universidad,, 2021 Full text Commentary |
Not reported/unclear | Methisoprinol | Standard care | RCT | Outpatients with confirmed COVID-19 (symptomatic) treated at home in Ecuador | N=60 | N/A | |
| NCT04392973 Bosaeed M, Infect Dis Ther, 2021 Full text Commentary |
Public/non profit | Favipiravir+Hydroxychloroquine | Standard care | RCT | Patients with confirmed COVID-19 (mild to critical) admitted to 9 centers in Saudi Arabia | N=268 |
Some concerns Details |
|
| NCT04329832 Brown SM, Ann Am Thorac Soc, 2020 Full text Commentary |
Public/non profit | Hydroxychloroquine | Azithromycin | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 13 centers in the USA | N=85 |
Some concerns Details |
|
| ISRCTN86534580 ; EudraCT 2020-001209-22 Butler C, Lancet , 2021 Full text Commentary |
Public/non profit | Azithromycin | Standard care | RCT | Outpatients with suspected or confirmed COVID-19 (mild) recruited in the community in the UK | N=540 |
High Details |
|
| ISRCTN86534580 Butler C, Lancet Respir Med, 2021 Full text Commentary |
Public/non profit | Doxycycline | Standard care | RCT | Outpatients with suspected or confirmed COVID-19 (symptomatic, mild) recruited in the community in the UK | N=827 |
Some concerns Details |
|
| NCT04860284 Byakika-Kibwika P, Research square , 2021 Full text Commentary Commentary |
Public/non profit | Hydroxychloroquine | Standard care | RCT | Outpatients with confirmed COVID-19 (asymptomatic and symptomatic, mild) isolated at a single center in Uganda. | N=105 |
Some concerns Details |
|
| NCT04729491 Cadegiani F, Cureus, 2021 Full text Commentary Commentary Commentary |
No specific funding | Dutasteride | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated by 5 centers in Brazil | N=130 |
Some concerns Details |
|
| NCT04728802 Cadegiani F, medRxiv, 2021 Full text Commentary Commentary |
Private | Proxalutamide | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 8 centers in Brazil. | N=645 |
Low Details |
|
| NCT04446429 Cadegiani FA, Cureus, 2021 Full text Commentary Commentary |
Mixed | Proxalutamide | Placebo | RCT | Male outpatients with confirmed COVID-19 (mild) treated at 2 centers in Brazil. | N=262 |
High Details |
|
| ChiCTR2000029308 Cao B, N Engl J Med, 2020 Full text Commentary Commentary |
Mixed | Lopinavir-Ritonavir | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in China. | N=199 |
Some concerns Details |
|
| ChiCTR-OPN-200002958 Cao Y, J Allergy Clin Immun, 2020 Full text Commentary |
Public/non profit | Ruxolitinib | Vitamin C | RCT | Patients with COVID-19 (severe) admitted to 3 centers in China. | N=43 |
Some concerns Details |
|
| NCT04362813; EudraCT 2020-001370-30 Caricchio R, JAMA, 2021 Full text Commentary |
Private | Canakinumab | Placebo | RCT | Patients with suspected or confirmed COVID-19 (mild-severe) admitted to 39 centers in France, Italy, Russia, Spain, UK and USA. | N=454 |
Low Details |
|
| NCT04473170 Carmenate Y, Research square , 2021 Full text Commentary Commentary |
Private | Autologous Non-Hematopoietic Peripheral Blood Stem Cells | Standard care | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 4 centers in United Arab Emirates. | N=143 |
High Details |
|
| NCT04322123 Cavalcanti AB, N Engl J Med, 2020 Full text Commentary |
Mixed | Hydroxychloroquine | Standard care | RCT | Patients with suspected or confirmed COVID-19 (mild-moderate) admitted to 55 centers in Brazil | N=667 |
Some concerns Details |
|
| Hydroxychloroquine + Azithromycin | Standard care | |||||||
| Hydroxychloroquine + Azithromycin | Hydroxychloroquine | |||||||
| NCT04390022 Chaccour C, EClinicalMedicine, 2021 Full text Commentary |
Mixed | Ivermectin | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) attending the emergency room at a single center in Spain | N=24 |
Some concerns Details |
|
| NCT04784481 Chahla R, Research Square, 2021 Full text Commentary |
Public/non profit | Ivermectin | Standard care | RCT | Outpatients with confirmed COVID-19 (mild) treated by multiple centers in Argentina. | N=254 |
Some concerns Details |
|
| ChiCTR2000030254 Chen C, Front Pharmacol, 2021 Full text Full text Commentary |
Public/non profit | Favipiravir | Umifenovir | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 3 centers in China | N=240 |
Some concerns Details |
|
| NCT04384380 Chen CP, Plos one, 2020 Full text Full text Commentary |
Mixed | Hydroxychloroquine | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to 11 centers in Taiwan | N=33 |
Some concerns Details |
|
| NCT04261517 Chen J, Journal of Zhejiang , 2020 Full text Commentary |
Public/non profit | Hydroxychloroquine | Standard care | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to a single center in China | N=30 |
High Details |
|
| NCT04252274 Chen J, Open Forum Infect Di, 2020 Full text Commentary |
Public/non profit | Darunavir/cobicistat | Standard care | RCT | Patients with COVID-19 (moderate) admitted to a single center in China | N=30 |
High Details |
|
| ChiCTR2000030054 Chen L, medRxiv, 2020 Full text Commentary |
Public | Hydroxychloroquine | Chloroquine | RCT | Patients with confirmed COVID-19 (mild, moderate) admitted to a single center in China | N=67 |
High Details |
|
| Chloroquine | Standard care | |||||||
| Hydroxychloroquine | Standard care | |||||||
| NCT04427501 Chen P, N Engl J Med, 2020 Full text Commentary |
Private | Bamlanivimab (LY-CoV555) | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated at 41 centers in USA | N=467 |
Low Details |
|
| ChiCTR2000029559 Chen Z, medRxiv, 2020 Full text Commentary Commentary |
Public/non profit | Hydroxychloroquine | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to a single center in China. | N=62 |
Some concerns Details |
|
| ChiCTR2000030007 Cheng L, JAMA Intern Med, 2020 Full text Commentary |
Mixed | rhG-CSF | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 3 centers in China | N=200 |
Some concerns Details |
|
| NCT04434144 Chowdhury ATMM, EJMO, 2021 Full text Commentary Commentary |
No specific funding | Ivermectin+Doxycycline | Hydroxychloroquine+Azithromycin | RCT | Outpatients with confirmed COVID-19 (asymptomatic, mild) treated by a single center in Bangladesh | N=125 |
High Details |
|
| NCT04377711 Clemency B, medRxiv, 2021 Full text Commentary Commentary |
Private | Ciclesonide | Standard Care | RCT | Outpatients with confirmed COVID-19 (mild, symptomatic) treated by 10 centers in the USA. | N=400 |
Some concerns Details |
|
| NCT04338009 Cohen J, Lancet Respir Med, 2021 Full text Commentary Commentary |
Mixed | Continue ARB/ACEI | Discontinue ARB/ACEI | RCT | Patients with suspected and confirmed COVID-19 (unclear severity) admitted to 20 centers in Argentina, Bolivia, Canada, Mexico, Peru, Sweden, USA | N=152 |
Some concerns Details |
|
| NCT04324073 CORIMUNO-SARI, Unpublished, 2021 |
Public/non profit | Standard care | Sarilumab | RCT | Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to multiple centers in France. | N=* |
Low Details |
|
| NCT04331808 CORIMUNO-TOCI-2 (ICU), Unpublished, 2021 |
Public/non profit | Standard care | Tocilizumab | RCT | Patients with suspected or confirmed COVID-19 (severe-critical) admitted to multiple centers in France. | N=* |
Low Details |
|
| EudraCT202000193437 Corral-Gudino L, medRxiv, 2020 Full text Commentary |
No specific funding | Methylprednisolone | Standard care | RCT | Patients with COVID-19 (severe) admitted to 5 centers in Spain | N=64 |
High Details |
|
| NCT04330638 COV-AID, Unpublished, 2021 |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (severe-critical) admitted to 16 centers in Belgium | N=153 |
Low Details |
|
| NCT04479358 COVIDOSE-2, Unpublished, 2021 |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to multiple centers in the USA | N=28 |
Low Details |
|
| NCT04577534 COVIDSTORM, Unpublished, 2021 |
Not reported/unclear | Standard care | Tocilizumab | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Finland. | N=39 |
Low Details |
|
| NCT04435717 COVITOZ-01, Unpublished, 2021 |
Public/non profit | Standard care | Tocilizumab | RCT | Patients with suspected or confirmed COVID-19 (mild-moderate-severe) admitted to a single center in Spain. | N=26 |
Low Details |
|
| NCT04399980, NCT04463004, NCT04492514 Cremer P, Lancet Rheumatol, 2021 Full text Commentary |
Private | Mavrilimumab | Placebo | RCT | Patients with confirmed COVID-19 (moderate/severe) admitted to 7 centers in the USA | N=40 |
Some concerns Details |
|
| NCT04365153 Cremer P, The three C study, 2021 Full text Commentary |
Private | Canakinumab 600mg | Placebo | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 2 centers in the USA | N=45 |
Some concerns Details |
|
| Canakinumab 600mg | Canakinumab 300mg | |||||||
| Canakinumab 300mg | Placebo | |||||||
| RPCEC00000317 Cruz LR, ACS Pharmacol. Trans, 2020 Full text Commentary Commentary |
Mixed | CIGB-325 | Standard care | RCT | Patients with confirmed COVID-19 (asymptomatic-severe) admitted to a single center in Cuba | N=20 |
Some concerns Details |
|
| NCT04351295 Dabbous H, Arch Virol, 2021 Full text Commentary |
Not reported/unclear | Favipiravir | Chloroquine | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to 2 centers in Egypt | N=96 |
Some concerns Details |
|
| NCT04521400 Darazam I, Int Immunopharmacol, 2021 Full text Full text Commentary |
Public/non profit | High dose Interferon-β 1a | Low dose Interferon-β 1a | RCT | Patients with T-PCR and/or chest CT confirmed COVID-19 (moderate-severe) admitted to a single center in Iran. | N=168 |
Some concerns Details |
|
| NCT04343768 Darazam IA, COVIFERON, 2021 Full text Commentary ; Commentary |
No specific funding | Interferon beta-1b | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Iran. | N=60 |
Some concerns Details |
|
| Interferon beta-1a | Standard care | |||||||
| Interferon beta-1b | Interferon beta-1a | |||||||
| IRCT20190727044343N1 Davoodi L, Int J Clin Pract, 2020 Full text Commentary |
Public/non profit | Febuxostat | Hydroxychloroquine | RCT | Outpatients with COVID-19 (mild-moderate) treated at a single center in Iran | N=60 |
Some concerns Details |
|
| IRCT20100228003449N28 Davoudi-Monfared E, Antimicrob Agents Ch, 2020 Full text Commentary |
Private | Interferon beta-1a | Standard care | RCT | Patients with COVID-19 (moderate to critical) admitted to a single center in Iran. | N=92 |
High Details |
|
| NCT04326790 Deftereos S, JAMA, 2020 Full text Commentary |
Private | Colchicine | Standard care | RCT | Patients with COVID-19 (moderate-severe) admitted to 16 centers in Greece. | N=110 |
Some concerns Details |
|
| RPCEC00000309 Delgado-Enciso I, Exp Ther Med, 2021 Full text Full text Commentary Commentary |
Mixed | Neutral electrolyzed saline | Standard care | RCT | Outpatients with confirmed COVID-19 (ambulatory, mild) treated at home in Mexico. | N=* |
Some concerns Details |
|
| NCT02517489 Dequin P-F, JAMA, 2020 Full text Commentary |
Public/non profit | Hydrocortisone | Placebo | RCT | Patients with COVID-19 (severe-critical) admitted to 9 centers in France | N=149 |
Some concerns Details |
|
| NCT02735707 Derde L, REMAP-CAP, 2021 Full text Commentary Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (moderate to critical) admitted to 133 centers in 9 countries | N=2253 |
Some concerns Details |
|
| Sarilumab | Standard care | |||||||
| Anakinra | Standard care | |||||||
| NCT04861298 Di Pierro F, Int J Gen Med, 2021 Full text Commentary |
Private | Quercetin | Standard care | RCT | Outpatients with confirmed COVID-19 (mild) treated at a single center in Pakistan | N=42 |
Some concerns Details |
|
| NCT04457609 Dilogo IH, Stem Cells Transl Med, 2021 Full text Commentary |
Public/non profit | Umbilical cord mesenchymal stromal cell infusion | Placebo | RCT | Patients with confirmed COVID-19 (critical) admitted to a 4 centers in Indonesia | N=40 | N/A | |
| jRCTs041190120 Doi Y, Antimicrob Agents Ch, 2020 Full text Commentary |
Mixed | Favipiravir | Favipiravir | RCT | Patients with confirmed COVID-19 (asymptomatic-mild-moderate) admitted to multiple centers in Japan | N=88 |
Some concerns Details |
|
| NCT04427501 Dougan M, N Engl J Med, 2021 Full text Commentary |
Private | LY-CoV555+LY-CoV016 | Placebo | RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated at multiple centers in USA. | N=1035 |
Some concerns Details |
|
| NCT04244591 Du, Unpublished, 2020 |
Public/non profit | Methylprednisolone | Standard care | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in China | N=47 |
Some concerns Details |
|
| NCT04355936 Duarte M, EClinicalMedicine, 2021 Full text Commentary |
Mixed | Telmisartan | Standard care | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to 2 centers in Argentina | N=162 |
Some concerns Details |
|
| NCT04325893 Dubee V, Clin Microbiol Infec, 2021 Full text Commentary Commentary |
Public/non profit | Hydroxychloroquine | Placebo | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to 34 centers in France and Monaco. | N=250 |
Some concerns Details |
|
| IRCT20200404046947N1 Edalatifard M, Eur Respir J, 2020 Full text Commentary |
Public/non profit | Intravenous Methylprednisolone pulse | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to two centers in Iran | N=68 |
Some concerns Details |
|
| N/A El-Bendary M, Expert Rev Anti-Infe, 2021 Full text Commentary |
No specific funding | Sofosbuvir+Daclatasvir | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate-severe) treated by or admitted to 3 centers in Egypt. | N=174 |
Some concerns Details |
|
| N/A Elamir YM, Bone, 2021 Full text Commentary |
Not reported/unclear | Calcitriol | Standard care | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 3 centers in USA. | N=50 |
Some concerns Details |
|
| NCT04530422 Elgohary M, medRxiv, 2021 Full text Commentary Commentary |
Not reported/unclear | Sofosbuvir+Ledipasvir | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to a single center in Egypt | N=250 |
Some concerns Details |
|
| NCT04366908 Entrenas Castillo M, J Steroid Biochem Mo, 2020 Full text Commentary |
Public/non profit | Calcifediol | Standard care | RCT | Patients with confimed COVID-19 (moderate-severe) admitted to a single center in Spain | N=76 |
Some concerns Details |
|
| NCT04602000; EudraCT: 2020-003369-20; CRIS: KCT000 Eom J, 2021 Full text Commentary Commentary |
Private | CT-P59 40mg/kg | Placebo | RCT | Outpatients with confirmed COVID-19 (mild symptomatic) treated at 23 centers in South Korea, Romania, Spain and USA | N=327 |
Low Details |
|
| CT-P59 40mg/kg | CT-P59 80mg/kg | |||||||
| CT-P59 80mg/kg | Placebo | |||||||
| RPCEC00000307 Esquivel-Moynelo I, medRxiv, 2020 Full text Commentary |
Public/non profit | IFN alpha2b+IFN gamma | Interferon alpha2b | RCT | Patients with confirmed COVID-19 (ambulatory, mild) admitted to a single center | N=79 |
High Details |
|
| NCT02735707 Estcourt L, medRxiv, 2021 Full text Commentary |
Mixed | Standard care | Convalescent plasma | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 129 centers in Australia, Canada, UK, USA | N=2000 |
Low Details |
|
| IRCT20151227025726N23 Fakharian A, Int Immunopharmacol, 2021 Full text Commentary |
Public/non profit | Adalimumab | Standard care | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran | N=68 |
Some concerns Details |
|
| IRCT20200406046963N1 Farahani R, Research Square, 2020 Full text Commentary |
Public/non profit | Intravenous Methylprednisolone pulse+Prednisolone | Standard care | RCT | Patients with COVID-19 (severe) admitted to a single center in Iran | N=29 | N/A | |
| NCT04354259 Feld JJ, Lancet Respir Med, 2021 Full text Commentary Commentary |
Mixed | Peginterferon Lambda-1 | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) tested at 6 centers in Canada | N=60 |
Some concerns Details |
|
| NCT04405570 Fischer W, 2021 Full text Commentary Commentary |
Mixed | Molnupiravir 400mg | Placebo | RCT | N=202 |
High Details |
||
| Molnupiravir 800mg | Placebo | |||||||
| Molnupiravir 200mg | Placebo | |||||||
| ISRCTN40580903, EudraCT 2020-001684-85 Fisher B, CATALYST, 2021 Full text Commentary Commentary |
Public/non profit | Namilumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to nine centers in the UK | N=146 |
Some concerns Details |
|
| Infliximab | Standard care | |||||||
| NCT04343963 Fragoso-Saavedra S, medRxiv, 2021 Full text Commentary Commentary |
Public/non profit | Pyridostigmine | Placebo | RCT | Patients with confirmed COVID-19 (severe) admitted to 2 centers in Mexico. | N=188 |
Some concerns Details |
|
| ChiCTR2000030262 Fu W, EClinicalMedicine, 2020 Full text Commentary |
Public/non profit | Interferon kappa+TFF2 | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to a single center in China | N=80 |
Some concerns Details |
|
| NCT04321278 Furtado RHM, Lancet, 2020 Full text |
Mixed | Azithromycin + Hydroxychloroquine | Hydroxychloroquine | RCT | Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 57 centers in Brazil | N=447 |
Some concerns Details |
|
| NCT04359095 Gaitan-Duarte H, 2021 Full text Commentary Commentary |
Public/non profit | Tenofovir/Emtricitabine | Standard care | RCT | Patients with suspected or confirmed COVID-19 (mild-critical) admitted to six centers in Colombia | N=649 |
Some concerns Details |
|
| Colchicine+Rosuvastatin | Standard care | |||||||
| Emtricitabine/tenofovir+Colchicine+Rosuvastatin | Standard care | |||||||
| RBR-8h7q82 Galan L ,Pathog Glob Health, 2021 Full text Commentary |
Public/non profit | Ivermectin | Hydroxychloroquine | RCT | Patients with serology or RT-PCR confirmed COVID-19 (moderate-critical) admitted to a single center in Brazil. | N=168 | N/A | |
| Ivermectin | Chloroquine | |||||||
| Hydroxychloroquine | Chloroquine | |||||||
| RBR-8969zg Garcia de Alencar JC, CID, 2020 Full text Commentary |
Public/non profit | N-acetylcysteine | Placebo | RCT | Patients with COVID-19 (mild-severe) admitted to a single center in Brazil | N=140 | N/A | |
| NCT04340557 Geriak M, Infect Dis Ther, 2021 Full text Commentary |
Private | Losartan | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to 3 centers in USA. | N=32 |
High Details |
|
| IRCT20200523047550N1 Ghaderkhani S, Research Square, 2021 Full text Commentary Commentary |
Public/non profit | Hydroxychloroquine+Umifenovir | Hydroxychloroquine | RCT | Outpatients with suspected or confirmed COVID-19 (mild-moderate) treated by a single center in Iran | N=56 | N/A | |
| NCT04365127 Ghandehari S, SSRN, 2020 Full text Commentary Commentary |
Private | Progesterone | Standard care | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to a single center in the USA. | N=42 |
Some concerns Details |
|
| IRCT20200318046812N2 Ghanei M, 2021 Full text Commentary |
Public/non profit | Prednisolone+Azithromycin+Naproxen | Lopinavir+Ritonavir | RCT | Patients with confirmed COVID-19 (severe) admitted to 6 centers in Iran. | N=352 |
Some concerns Details |
|
| Azithromycin+Naproxen | Lopinavir+Ritonavir | |||||||
| Prednisolone+Azithromycin+Naproxen | Azithromycin+Naproxen | |||||||
| NCT04342182 Gharbharan A, Nat Commun, 2021 Full text Commentary |
Mixed | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 14 centers in the Netherlands | N=86 |
Some concerns Details |
|
| IRCT20200501047259N1 Gharebaghi N, BMC Infect Dis., 2020 Full text Commentary |
Public/non profit | Intravenous Immunoglobulin | Placebo | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Iran | N=59 | N/A | |
| CTRI/2020/07/026791 Ghati N, Removed from SSRN Full text Commentary Commentary |
No specific funding | Atorvastatin | Standard care | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to a single center in India | N=900 |
Some concerns Details |
|
| Atorvastatin | Aspirin | |||||||
| Atorvastatin | Atorvastatin+Aspirin | |||||||
| Aspirin | Standard care | |||||||
| Aspirin | Atorvastatin+Aspirin | |||||||
| Atorvastatin+Aspirin | Standard care | |||||||
| NCT04292899 Goldman JD, N Engl J Med, 2020 Full text Results in clinicaltrials.gov Full text Commentary Commentary |
Private | Remdesivir 5 days | Remdesivir 10 days | RCT | Patients with confirmed COVID-19 (moderate to critical) admitted to 55 centers across 5 countries. | N=402 |
Some concerns Details |
Forest plots |
| ISRCTN59048638 Gonzalez-Ochoa AJ , Thromb Haemost, 2021 Full text Commentary Commentary |
Private | Sulodexide | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) of a single center in Mexico | N=312 |
Some concerns Details |
|
| NCT02735707 Gordon AC, REMAP-CAP, 2021 Full text Commentary Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed or suspected COVID-19 (severe-critical) admitted to 113 centers in Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK. | N=826 |
Some concerns Details |
|
| Sarilumab | Standard care | |||||||
| NCT04427501 Gottlieb R, BLAZE-1, 2021 Full text Commentary Commentary |
Private | LY-CoV555 700 mg | Placebo | RCT | Outpatients with COVID-19 (mild ambulatory) treated at 49 centers in USA | N=592 |
Some concerns Details |
|
| LY-CoV555 2800 mg | Placebo | |||||||
| LY-CoV555 7000 mg | Placebo | |||||||
| LY-CoV555+LY-CoV016 | Placebo | |||||||
| NCT04469114 Guimaraes P, N Engl J Med, 2021 Full text Commentary |
Private | Tofacitinib | Placebo | RCT | Patients with confirmed COVID-19 (mild-moderate-severe) admitted to 15 centers in Brazil | N=289 |
Low Details |
|
| NCT04321096 ; EudraCT Number: 2020001,20042 Gunst J, EClinicalMedicine, 2021 Full text Commentary |
Private | Camostat Mesilate | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 9 centers in Denmark and Sweden. | N=208 |
Some concerns Details |
|
| NCT04545060 Gupta A, medRxiv, 2021 Full text Commentary |
Private | Sotrovimab | Placebo | RCT | Outpatients with confirmed COVID-19 (mild)and at high risk for Covid-19 progression, treated by 37 centers in the USA, Canada, Brazil, and Spain. | N=583 |
Low Details |
|
| N/A Guvenmez O, J Popul Ther Clin Ph, 2020 Full text Commentary |
No specific funding | Lincomycin | Azithromycin | RCT | Patients with confirmed COVID-19 (moderate) admitted to a single center in Turkey | N=24 |
Some concerns Details |
|
| N/A Hamed D M, J Infect Public Heal, 2021 Full text Commentary |
No specific funding | Methylprednisolone | Methylprednisolone +Tocilizumab | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Dubai. | N=49 |
Some concerns Details |
|
| NCT04414124 Haran J, medRxiv, 2021 Full text Commentary Commentary |
Private | KB109 | Standard care | RCT | Outpatients with confirmed COVID-19 (mild) treated by 16 centers in the USA. | N=350 |
Some concerns Details |
|
| NCT04591600 Hashim A, medRxiv, 2020 Full text Commentary Commentary |
Public/non profit | Ivermectin+Doxycycline | Standard care | RCT | Outpatients and inpatients with COVID-19 (unclear severity) treated at 2 centers in Iraq | N=140 |
High Details |
|
| NCT04331808 Hermine O, JAMA Intern Med, 2020 Full text Commentary |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with COVID-19 (moderate-severe) admitted to nine centers in France | N=131 |
Some concerns Details |
|
| NCT04476979 Hermine O, SSRN, 2021 Full text Commentary Commentary |
Public/non profit | Tocilizumab + Dexamethasone | Dexamethasone | RCT | Patients with confirmed COVID-19 (moderate) admitted to 25 centers in France and French Guyana. | N=453 |
Some concerns Details |
|
| NCT04315896 Hernandez-Cardenas C, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Hydroxychloroquine | Placebo | RCT | Patients with RT-PCR confirmed COVID-19 (severe-critical) admitted to 3 centers in Mexico | N=214 |
Some concerns Details |
|
| NCT04381962 Hinks T, Lancet Respir Med, 2021 Full text 00263-0/fulltext Commentary Commentary |
Mixed | Azithromycin | Standard care | RCT | Outpatients with suspected or confirmed COVID-19 (mild) treated at 19 centers in the UK. | N=295 |
Some concerns Details |
|
| NCT04377750 HMO-0224-20, Unpublished, 2021 |
Public/non profit | Placebo | Tocilizumab | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in Israel. | N=54 |
High Details |
|
| NCT04682873 Holubovska O, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Enisamium | Placebo | RCT | Patients with confirmed COVID-10 (mild/moderate) admitted to 15 centers in Ukraine | N=* | N/A | |
| NCT04381936, EudraCT 2020-001113-21, ISRCTN5018967 Horby P(2), medRxiv, 2021 Full text Commentary Commentary |
Mixed | Casirivimab+Imdevimab (REGN-COV2) | Standard care | RCT | Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 127 centers in the UK | N=9785 |
Some concerns Details |
|
| NCT04381936 Horby P, Lancet, 2020 Full text Commentary |
Mixed | Lopinavir-Ritonavir | Standard care | RCT | Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 163 centers in the UK | N=5040 |
Some concerns Details |
|
| NCT04381936 ; ISRCTN (50189673) Horby P, Lancet, 2021 Full text Commentary Commentary |
Mixed | Azithromycin | Standard care | RCT | Patients with suspected or confirmed COVID-19 (mild to critical) admitted to 176 centers in the UK | N=7763 |
Some concerns Details |
|
| NCT04381936, ISRCTN50189673 Horby P, Lancet, 2021 Full text Commentary Commentary |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 131 centers in the UK | N=4116 |
Some concerns Details |
|
| NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967 Horby P, Lancet, 2021 Full text Commentary Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with suspected or confirmed COVID-19 (mild-moderate-severe-critical) admitted to 177 centers in the UK. | N=11558 |
Some concerns Details |
|
| NCT04381936 ; ISRCTN50189673 Horby P, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Colchicine | Standard care | RCT | Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 177 centers in the UK, 2 centers in Indonesia, and 2 centers in Nepal | N=11340 |
Some concerns Details |
|
| NCT04381936; ISRCTN50189673 Horby P, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Aspirin | Standard care | RCT | Patients with suspected and confirmed COVID-19 (mild-critical) admitted to 177 centers in the UK, 2 centers in Indonesia and 2 centers in Nepal | N=14892 |
Some concerns Details |
|
| NCT04381936 Horby P, N Engl J Med, 2020 Full text Commentary |
Mixed | Hydroxychloroquine | Standard care | RCT | Patients with COVID-19 (mild-critical) admitted to 176 centers in the UK | N=4716 |
Some concerns Details |
|
| NCT04381936 RECOVERY Trial Horby P, N Engl J Med, 2021 Full text Commentary |
Mixed | Dexamethasone | Standard care | RCT | Patients with suspected and confirmed COVID-19 (mild-moderate-critical) admitted to 176 centers in the UK | N=6425 |
Some concerns Details |
Forest plot (sub group) |
| ChiCTR2000029387 Huang YQ, Front Pharmacol, 2020 Full text Commentary |
Public/non profit | Ribavirin+Lopinavir+Ritonavir+Interferon alpha | Ribavarin+Interferon alpha | RCT | Patients with confirmed COVID-19 (moderate) admitted to a single center in China | N=101 |
Some concerns Details |
|
| Lopinavir+Ritonavir+Interferon alpha | Ribavarin+Interferon alpha | |||||||
| Ribavirin+Lopinavir+Ritonavir+Interferon alpha | Lopinavir+Ritonavir+Interferon alpha | |||||||
| NCT04276688 Hung IF-N, Lancet, 2020 Full text Commentary Commentary |
Public/non profit | LPV/r+RBV+IFN beta1 | Lopinavir-Ritonavir | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to six centers in Hong-Kong | N=127 |
Some concerns Details |
|
| NCT04412291, EudraCT 2020-001748-24 IMMCOVA, Unpublished, 2021 |
Public/non profit | Standard care | Tocilizumab | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a multiple centerd in Sweden | N=49 |
Low Details |
|
| NCT04434248 Ivashchenko AA, Clin Infect Dis, 2020 Full text Commentary |
Mixed | Favipiravir 1800/800mg | Favipiravir 1600/600mg | RCT | Patients with confirmed COVID-19 (moderate) admitted to 6 centers in Russia | N=60 |
Some concerns Details |
|
| Favipiravir 1600/600mg | Standard care | |||||||
| Favipiravir 1800/800mg | Standard care | |||||||
| NCT04331899 Jagannathan P, Nature, 2021 Full text Commentary Commentary |
Mixed | Placebo | Peginterferon Lambda-1a | RCT | Outpatients with confirmed COVID-19 (asymptomatic/symptomatic, mild) treated at a single center in the USA | N=120 |
Some concerns Details |
|
| IRCT20151227025726N17 Jamaati H, Eur J Pharmacol, 2021 Full text Commentary |
Public/non profit | Dexamethasone | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Iran | N=50 |
Some concerns Details |
|
| IRCT20200411047025N1 JamaliMoghadamSiahkali S, Eur J Med Res, 2021 Full text Commentary |
Public/non profit | Vitamin C | Standard care | RCT | Patients with suspected or confirmed COVID-19 (severe) admitted to a single center in Iran | N=60 | N/A | |
| NCT04354428 Johnston C, 2021 Full text Commentary Commentary Commentary |
Public/non profit | Hydroxychloroquine+Azithromycin | Vitamin C+Placebo | RCT | Outpatients with confirmed COVID-19 (asymptomatic-mild) treated by 5 centers in the USA | N=231 |
Some concerns Details |
|
| Hydroxychloroquine+Azithromycin | Hydroxychloroquine+Placebo | |||||||
| Hydroxychloroquine+Placebo | Vitamin C+Placebo | |||||||
| IRCT20210214050350N1 Kalantari S, J Med Virol, 2021 Full text Commentary |
Public/non profit | Atazanavir+Ritonavir+Dolutegravir+Hydroxychloroquine | Hydroxychloroquine+Lopinavir+Ritonavir | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Iran | N=* | N/A | |
| NCT04401579 Kalil AC, N Engl J Med, 2020 Full text Commentary |
Public/non profit | Baricitinib+Remdesivir | Placebo+Remdesivir | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 67 centers in Denmark, Japan, Mexico, Singapore, South Korea, Spain, UK, USA. | N=1033 |
Low Details |
|
| NCT04491994 Kamran S M, Cureus, 2021 Full text Commentary Commentary |
No specific funding | Hydroxychloroquine | Standard care | RCT | Patients with confirmed COVID-19 (mild) admitted to a single center in Pakistan | N=540 |
High Details |
|
| N/A Khamis F, Int J Infect Dis, 2020 Full text Commentary |
No specific funding | Favipiravir+Interferon beta-1b | Hydroxychloroquine | RCT | Patients with confirmed COVID-19 (moderate-severe) treated at a single center in Oman | N=89 |
Some concerns Details |
|
| NCT04739410 Khan Chachar AZ, Int J Sci, 2020 Full text Commentary |
No specific funding | Ivermectin | Standard care | RCT | Outpatients with confirmed COVID-19 (symptomatic-mild) treated at a single center in Pakistan | N=50 |
High Details |
|
| NCT04542941 Kirenga B, BMJ Open Respir Res, 2021 Full text Commentary Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (asymptomatic-severe) admitted to a single center in Uganda. | N=136 |
Some concerns Details |
|
| N/A Kishoria N, PIJR, 2020 Full text Commentary |
Not reported/unclear | Ivermectin | Standard care | RCT | Patients with confirmed COVID-19 (mild/asymptomatic) admitted to a single center in India. | N=32 |
Some concerns Details |
|
| DRKS00024520; EudraCT 2020-005544-34 Klussmann J, 2021 Full text Commentary Commentary |
Private | Azelastine 0.02 | Placebo | RCT | Outpatients with confirmed COVID-19 (asymptomatic and mild) treated at a single center in Germany. | N=90 | N/A | |
| Azelastine 0.1 | Placebo | |||||||
| Azelastine 0.02 | Azelastine 0.1 | |||||||
| NCT04433910; EudraCT 2020-001310-38 Koerper S, J Clin Invest, 2021 Full text Full text Commentary Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 13 centers in Germany. | N=105 |
Some concerns Details |
|
| NCT04355767 Korley F, N Engl J Med, 2021 Full text rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Commentary |
Public/non profit | Convalescent plasma | Placebo | RCT | Outpatients and patients with confirmed COVID-19 (symptomatic, mild to moderate) treated at or admitted to 48 centers in the USA. | N=511 |
Some concerns Details |
|
| NCT04350593 Kosiborod M, Lancet Diabetes Endo, 2021 Full text 00180-7/fulltext Commentary |
Private | Dapagliflozin | Placebo | RCT | Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to 95 hospitals in Argentina, Brazil, Canada, India, Mexico, UK, USA. | N=1250 |
Low Details |
|
| NCT04412018 Kosmopoulos A, iScience, 2021 Full text Commentary Commentary |
Private | Icosapent ethyl | Standard care | RCT | Outpatients with confirmed COVID-19 (mild ambulatory) treated at a single center in Canada. | N=100 |
Some concerns Details |
|
| NCT04381884 Krolewiecki A, EClinicalMedicine, 2021 Full text Full text Commentary Commentary |
Mixed | Ivermectin | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to 4 centers in Argentina | N=45 |
Some concerns Details |
|
| CTRI/2020/05/024959 Kumar S, Exp Opin Biol Ther, 2021 Full text Commentary Commentary |
Private | Itolizumab | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to 4 centers in India | N=32 |
Some concerns Details |
|
| N/A Kumari P, Cureus, 2020 Full text Commentary Commentary |
Not reported/unclear | Vitamin C | Standard care | RCT | Patients with COVID-19 (severe) admitted to a single center in Pakistan | N=150 | N/A | |
| NCT04680949; EudraCT 2020-005828-11 Kyriazopoulou E, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Anakinra | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 37 centers in Greece and Italy | N=606 |
Some concerns Details |
|
| NCT04364022; SNCTP 000003732 Labhardt N, COPEP, 2021 Full text Commentary |
Public/nonprofit | Lopinavir-Ritonavir | Standard care | RCT | Asymptomatic individuals ?16 years close contacts with a person with a confirmed SARS-CoV-2 infection | N=321 |
Some concerns Details |
|
| NCT04355728 Lanzoni G, Stem Cells Transl Me, 2021 Full text Full text Commentary Commentary |
Mixed | Placebo | Umbilical cord mesenchymal stem cell infusion | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in USA | N=24 |
Some concerns Details |
|
| CTRI/2020/10/028423 Lattman E, medRxiv, 2021 Full text Commentary Commentary |
Private | PNB001 | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in India. | N=40 |
Some concerns Details |
|
| NCT02735707, NCT04505774, NCT04359277, NCT04372589 Lawler PR, N Engl J Med, 2021 Full text Full text Commentary |
Mixed | Therapeutic Heparin | Prophylactic anticoagulant | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 121 centers in Australia, Brazil, Canada, Mexico, Nepal, Netherlands, Spain, UK, USA. | N=2244 |
Some concerns Details |
|
| RBR-949z6v Lemos ACB, Thromb Res, 2020 Full text Commentary |
No specific funding | Therapeutic enoxaparin | Prophylactic anticoagulant | RCT | Patients with confirmed COVID-19 (critical) admitted to a single center in Brazil | N=20 |
Some concerns Details |
|
| NCT04342663 Lenze E, JAMA, 2020 Full text Commentary Commentary |
Mixed | Fluvoxamine | Placebo | RCT | Outpatients with confirmed COVID-19 (ambulatory, mild) treated at home in USA | N=181 |
Low Details |
|
| NCT04327388; EudraCT2020-001162-12; U1111-1249-602 Lescure FX, 2021 Full text Commentary Commentary |
Private | Sarilumab 400mg | Placebo | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 45 centers in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. | N=420 |
Some concerns Details |
|
| Sarilumab 200mg | Placebo | |||||||
| Sarilumab 400mg | Sarilumab 200mg | |||||||
| ChiCTR2000029638 Li C, Ann. Med, 2021 Full text Commentary Commentary |
Mixed | Recombinant super-compound interferon | Interferon alpha | RCT | Patients with COVID-19 (moderate-severe) admitted to 5 centers in China | N=96 |
Some concerns Details |
|
| ChiCTR2000029757 Li L, JAMA, 2020 Full text Commentary Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with COVID-19 (severe to critical) admitted to 7 centers in China | N=103 |
Some concerns Details |
|
| NCT04273763 Li T, Clin Transl Sci , 2020 Full text Commentary |
Public/non profit | Bromhexine | Standard care | RCT | Patients with confirmed or suspected COVID-19 (mild-moderate) admitted to a single center in China | N=18 |
Some concerns Details |
|
| NCT04479163 Libster R, N Engl J Med, 2021 Full text Commentary |
Public/non profit | Convalescent plasma | Placebo | RCT | Patients with confirmed COVID-19 (mild) admitted to multiple centers in Argentina | N=160 |
Some concerns Details |
|
| EudraCT 2020-001243-1 Liesenborghs L, SSRN, 2020 Full text Commentary Commentary |
Public/non profit | Itraconazole | Standard care | RCT | Patients with confirmed or suspected COVID-19 (unclear severity) admitted to a single center in Belgium | N=* |
Some concerns Details |
|
| ChiCTR2000030016 Lin YR, J Aerosol Med Pulm Drug Deliv, 2021 Full text Commentary |
Public/non profit | Mycobacterium vaccae | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to a single center in China. | N=31 |
Some concerns Details |
|
| NCT04397562 Lomakin N V, Inflamm Res, 2021 Full text Commentary |
Private | Levilimab | Placebo | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 12 centers in Russia | N=206 |
Some concerns Details |
|
| NCT04494984 Lopardo G, EClinicalMedicine, 2021 Full text Commentary Commentary |
Mixed | INM005 | Placebo | RCT | Patients with confirmed (RT-PCR) COVID-19 (mild-severe) pneumonia admitted to 19 centers in Argentina | N=245 |
Some concerns Details |
|
| RBR-8jyhxh Lopes MIF, RMD Open, 2021 Full text Commentary |
Public/non profit | Colchicine | Placebo | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Brazil | N=75 |
Some concerns Details |
|
| NCT04364893 Lopes RD, JAMA, 2021 Full text Commentary |
Not reported/unclear | Discontinue ARB/ACEI | Continue ARB/ACEI | RCT | Patients with suspected COVID-19 (unclear severity) at 29 centers in Brazil | N=740 |
Low Details |
|
| NCT04394377 Lopes RD, Lancet , 2021 Full text Commentary Commentary |
Mixed | Therapeutic anticoagulant | Prophylactic anticoagulant | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 31 centers in Brazil | N=615 |
Some concerns Details |
|
| NCT04405843 Lopez-Medina E, JAMA, 2021 Full text Commentary Commentary |
Mixed | Ivermectin | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated by a single center in Colombia | N=476 |
Some concerns Details |
|
| ChiCTR2000029544 Lou Y, 2020 Full text Commentary |
Public/non profit | Favipiravir | Standard care | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to a single center in China | N=30 |
Some concerns Details |
|
| Baloxavir marboxil | Standard care | |||||||
| Favipiravir | Baloxavir marboxil | |||||||
| NCT04501978 Lundgren J, medRxiv, 2021 Full text Full text Commentary |
Mixed | Bamlanivimab (LY-CoV555) | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 31 centers in Denmark, Singapore and USA | N=326 |
Some concerns Details |
|
| NCT04316377 Lyngbakken MN, Nature, 2020 Full text Commentary |
Public/non profit | Hydroxychloroquine | Standard care | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Norway | N=53 |
High Details |
|
| N/A Mahajan L, Indian J Anaesth, 2021 Full text Commentary |
No specific funding | Remdesivir | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in India. | N=82 |
High Details |
|
| NCT04523831 Mahmud R, J Int Med Res, 2021 Full text Commentary |
No specific funding | Ivermectin+Doxycycline | Placebo | RCT | Outpatients and inpatients with confirmed COVID-19 (ambulatory-mild-moderate) admitted to a single center in Bangladesh | N=400 |
Some concerns Details |
|
| N/A Maldonado V, INT IMMUNOPHARMACOL, 2020 Full text Commentary |
No specific funding | Pentoxifylline | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Mexico | N=54 | N/A | |
| RBR-5s2mqg Mansour E, medRxiv, 2020 Full text Commentary |
Public/non profit | Icatibant | Standard care | RCT | Patients with COVID-19 (severe) admitted to a single center in Brazil | N=30 |
Some concerns Details |
|
| C1 Esterase/Kallikrein Inhibitor | Standard care | |||||||
| Icatibant | C1 Esterase/Kallikrein Inhibitor | |||||||
| NCT04421027 Marconi V, Lancet Respir Med, 2021 Full text Full text Full text Commentary Commentary |
Private | Baricitinib | Placebo | RCT | Patients with confirmed COVID-19 (mild-moderate-severe) admitted to 101 centers in Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, UK, USA | N=1525 |
Some concerns Details |
|
| NCT04341584 Mariette X, Lancet Respir Med, 2021 Full text Commentary |
Public/non profit | Anakinra | Standard care | RCT | Patients with COVID-19 (moderate) admitted to 16 centers in France. | N=116 |
Some concerns Details |
|
| NCT04790786 McCreary E, OPTIMISE-C19, 2021 Full text Commentary Commentary |
Public/non profit | LY-CoV555 | Casirivimab+Imdevimab (REGN-COV2) | RCT | Outpatients with confirmed COVID-19 (mild) treated at multiple ED or outpatient infusion centers or at home in the USA. | N=1935 |
Some concerns Details |
|
| LY-CoV555+LY-CoV016 | Casirivimab+Imdevimab (REGN-COV2) | |||||||
| LY-CoV555 | LY-CoV555+LY-CoV016 | |||||||
| NCT04468646 Mehboob R, medRxiv, 2020 Full text Commentary |
No specific funding | Aprepitant+Dexamethasone | Dexamethasone | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to a single center in Pakistan | N=41 |
Some concerns Details |
|
| NCT04345614 Miller J, Crit Care, 2020 Full text Commentary |
Private | Auxora | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to 3 centers in USA | N=26 |
Some concerns Details |
|
| NCT04304053 Mitja O, Clin Infect Dis, 2020 Full text Commentary |
Mixed | Hydroxychloroquine | Standard care | RCT | Outpatients with COVID-19 (mild) in an ambulatory setting in Spain | N=353 |
Some concerns Details |
|
| IRCT20200624047908N1 Mobarak S, SSRN, 2021 Full text Commentary Commentary |
Public/non profit | Sofosbuvir-Daclatasvir | Placebo | RCT | Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to 19 centers in Iran | N=1083 |
Some concerns Details |
|
| CTRI/2020/06/026001 Mohan A, 2021 Full text Commentary |
Mixed | Ivermectin 12 mg | Placebo | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India | N=152 |
Some concerns Details |
|
| Ivermectin 24 mg | Placebo | |||||||
| Ivermectin 12 mg | Ivermectin 24 mg | |||||||
| ISRCTN16806663 Moni M, medRxiv, 2021 Full text Commentary Commentary |
Public/non profit | Inhaled Nitric Oxide | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in India. | N=29 |
High Details |
|
| NCT04385095 ; EudraCT 2020-001023-14 Monk PD, Lancet Respir Med, 2020 Full text Commentary Commentary |
Private | Nebulised interferon beta-1a | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to nine centers in the UK | N=101 |
Some concerns Details |
|
| * Moreira TG, 2021 Full text Commentary Commentary |
Private | Foralumab | Standard care | RCT | Outpatients with confirmed COVID-19 (mild) treated at a single center in Brazil. | N=39 |
High Details |
|
| Foralumab+Dexamethasone | Standard care | |||||||
| Foralumab | Foralumab+Dexamethasone | |||||||
| NCT04509973 Munch M, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Dexamethasone 12mg | Dexamethasone 6mg | RCT | Patients with confirmed COVID-19 (severe/critical) admitted to 26 centers in Denmark (11), India (12), Sweden (2) and Switzerland (1). | N=982 |
Some concerns Details |
|
| NCT04348305 Munch MW, Acta Anaesthesiol Sc, 2021 Full text Commentary |
Mixed | Hydrocortisone | Placebo | RCT | Patients with confirmed COVID-19 (severe/critical) admitted to 12 centers in Denmark | N=30 |
Low Details |
|
| NCT04449718 Murai IH, Jama, 2021 Full text Commentary Commentary |
Public/non profit | Placebo | Cholecalciferol | RCT | Patients with COVID-19 (mild-severe) admitted to 2 centres in Brazil | N=240 |
Some concerns Details |
|
| NCT04334148 Naggie S Full text Commentary Commentary |
Public/nonprofit | Hydroxychloroquine | Placebo | RCT | NR | N=1360 |
Some concerns Details |
|
| IRCT20151113025025N3 Najmeddin F, Am J Hypertens, 2021 Full text Commentary |
Public/non profit | Continue ARB/ACEI | Discontinue ARB/ACEI | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 3 centers in Iran. | N=66 |
Some concerns Details |
|
| IRCT20200408046987N1 Niaee MS, Asian Pac J Trop Med, 2021 Full text Commentary Commentary |
Mixed | Ivermectin Once-off | Standard care | RCT | Patients with CT or PCR confirmed COVID-19 (unclear severity) admitted to 5 centers in Iran. | N=180 |
Some concerns Details |
|
| Ivermectin Once-off | Placebo | |||||||
| Ivermectin 3-day LD | Standard care | |||||||
| Ivermectin 3-day LD | Placebo | |||||||
| Ivermectin 1-day BDS | Standard care | |||||||
| Ivermectin 1-day BDS | Placebo | |||||||
| Ivermectin 3-day HD | Standard care | |||||||
| Ivermectin 3-day HD | Placebo | |||||||
| IRCT20180725040596N2 Nojomi M, BMC Infect Dis., 2020 Full text Commentary |
Public/non profit | Hydroxychloroquine+Umifenovir | Hydroxychloroquine+Lopinavir-Ritonavir | RCT | Patients with COVID-19 (moderate-severe) admitted to a single center in Iran | N=100 |
Some concerns Details |
|
| IRCT20180802040678N4 Nouri-Vaskeh M, Int J Clin Pract, 2021 Full text Commentary |
Public/non profit | Losartan | Amlodipine | RCT | Patients with confirmed COVID-19 (mild-moderate-severe-critical) admitted to a single center in Iran | N=82 |
Some concerns Details |
|
| IRCT20100228003449N29 Nourian A, Acta Biomed, 2020 Full text Commentary |
Mixed | Sofosbuvir-ledipasvir | Standard care | RCT | Patients with suspected or confirmed COVID-19 (mild-severe) admitted to a single center in Iran | N=90 |
Some concerns Details |
|
| NCT04452318 O Brien M P, medRxiv, 2021 Full text Full text Commentary Commentary |
Mixed | Casirivimab+Imdevimab (REGN-COV2) | Placebo | RCT | Outpatients with confirmed COVID-19 (mild, asymptomatic) treated at 112 centers in the Moldova, Romania, and USA. | N=314 |
Some concerns Details |
|
| NCT04359810 O Donnell M, J Clin Invest, 2021 Full text Commentary Commentary |
Not reported/unclear | Convalescent plasma | Control plasma | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to 5 centers in Brazil and USA | N=223 |
Low Details |
|
| NCT04646109 Okumus N, BMC Infectious Disea, 2021 Full text Commentary Commentary |
Public/non profit | Ivermectin | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to four centers in Turkey | N=66 |
High Details |
|
| NCT04332107 Oldenburg CE, JAMA, 2021 Full text Commentary Commentary |
Mixed | Azithromycin | Placebo | RCT | Outpatients with confirmed COVID-19 (mild, asymptomatic and symptomatic) enrolled in the community in the USA. | N=263 |
Some concerns Details |
|
| NCT04349592 Omrani A, Q-PROTECT, 2020 Full text Commentary |
Public/non profit | Hydroxychloroquine+Azithromycin | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated by 2 centers in Qatar | N=456 |
Some concerns Details |
|
| Hydroxychloroquine+Azithromycin | Hydroxychloroquine | |||||||
| Hydroxychloroquine | Placebo | |||||||
| CTRI/2020/05/025013 Padmanabhan U, medRixv, 2020 Full text Commentary Commentary |
Mixed | Bacille Calmette-Guérin | Placebo | RCT | “Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in India” | N=60 |
Some concerns Details |
|
| ISRCTN83971151; NCT04315948 Pan H, N Engl J Med, 2020 Full text Full text Commentary |
Mixed | Remdesivir | Standard care | RCT | Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries | N=5475 |
Low Details |
|
| ISRCTN83971151; NCT04315948 Pan H, N Engl J Med, 2020 Full text Full text Commentary |
Mixed | Interferon beta-1a | Standard care | RCT | Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries. | N=4127 |
Low Details |
|
| ISRCTN83971151; NCT04315948 Pan H, N Engl J Med, 2020 Full text Full text Commentary |
Mixed | Lopinavir-Ritonavir | Standard care | RCT | Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries. | N=2791 |
Low Details |
|
| ISRCTN83971151; NCT04315948 Pan H, N Engl J Med, 2020 Full text Full text Commentary |
Mixed | Hydroxychloroquine | Standard care | RCT | Patients with COVID-19 (mild-critical) admitted to 405 centers in 30 countries | N=1863 |
Low Details |
|
| CTRI/2020/06/026087 Pandit A, Int J Infect Dis, 2021 Full text Commentary |
Private | Pegylated Interferon alpha-2b | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in India | N=40 |
Some concerns Details |
|
| NCT04685512; EuraCT 2020-001867-94 Parientia JJ, EClinicalMedicine, 2021 Full text Commentary |
Public/non profit | Tenofovir+Emtricitabine | Standard care | RCT | Outpatients with confirmed COVID-19 (mild, symptomatic) treated by 2 centers in France | N=60 |
Some concerns Details |
|
| NCT04350320 ; EUDRACT 2020-001511-2 Pascual-Figal DA, Int J Gen Med, 2021 Full text Commentary |
Public/non profit | Colchicine | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to hospital in Spain. | N=103 |
Some concerns Details |
|
| NCT04376684 Patel J, medRxiv, 2021 Full text Commentary Commentary |
Private | Otilimab | Placebo | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 108 centers in 17 countries | N=806 |
Some concerns Details |
|
| ACTRN12620000454976 Patel O, J Med Virol, 2021 Full text Commentary |
Public/non profit | Zinc | Placebo | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to a single center in Australia | N=33 |
Low Details |
|
| NCT04360824 Perepu U, J Thromb Haemost, 2021 Full text Full text Commentary |
Public/non profit | Intermediate-Dose Enoxaparin | Standard-Dose prophylactic anticoagulation | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 3 centers in the USA. | N=176 |
Low Details |
|
| NCT04412057 Perlin DS , medRxiv, 2021 Full text Commentary Commentary |
Private | CERC-002 | Placebo | RCT | Patients with confirmed COVID-19 (severe) admitted to 11 centers in the USA | N=83 | N/A | |
| NCT04348305 Perner A, Unpublished, 2020 |
Mixed | Hydrocortisone | Placebo | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 19 centers in Denmark. | N=29 |
Low Details |
|
| N/A Podder C, IMC J Med Sci, 2020 Full text |
No specific funding | Ivermectin | Standard care | RCT | Outpatients with confirmed COVID-19 (mild-moderate) treated at a single center in Bangladesh | N=* |
Details |
|
| NCT04431466 Pott-Junior H, 2021 Full text Commentary |
No specific funding | Ivermectin 100 mcg/kg | Standard care | RCT | Patients with RT-PCR confirmed COVID-19 (symptomatic mild) admitted to a single center in Brazil. | N=32 |
Some concerns Details |
|
| Ivermectin 100 mcg/kg | Ivermectin 200 mcg/kg | |||||||
| Ivermectin 100 mcg/kg | Ivermectin 400 mcg/kg | |||||||
| Ivermectin 200 mcg/kg | Standard care | |||||||
| Ivermectin 200 mcg/kg | Ivermectin 400 mcg/kg | |||||||
| Ivermectin 400 mcg/kg | Standard care | |||||||
| IRCT20200310046736N1 Pouladzadeh M, Intern Emerg Med, 2021 Full text Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran | N=62 |
Some concerns Details |
|
| NCT04343729 Prado Jeronimo CM, Clin Infect Dis, 2020 Full text Commentary |
Public/non profit | Methylprednisolone | Placebo | RCT | Patients with COVID-19 (moderate-critical) admitted to a single center in Brazil | N=416 |
High Details |
|
| INA-TX6YYSS Purwati, 2021 Full text Commentary |
Public/non profit | Lopinavir-Ritonavir(Low dose)+Azithromycin | Azithromycin | RCT | NR | N=759 | N/A | |
| Lopinavir-Ritonavir(Low dose)+Doxycycline | Azithromycin | |||||||
| Hydroxychloroquine+Azithromycin | Azithromycin | |||||||
| Lopinavir-Ritonavir+Azithromycin | Azithromycin | |||||||
| Lopinavir-Ritonavir+Doxycycline | Azithromycin | |||||||
| NCT04311177 Puskarich M, EClinicalMedicine, 2021 Full text Commentary |
Public/non profit | Losartan | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated at 3 centers in the USA | N=117 |
Low Details |
|
| NCT04312009 Puskarich M, medRxiv, 2021 Full text Commentary Commentary |
Public/non profit | Losartan | Placebo | RCT | Patients with confirmed COVID-19 (mild - critical) admitted to 13 centers in the US. | N=205 |
Some concerns Details |
|
| IRCT20100228003449N27 Rahmani H, Int Immunopharmacol, 2020 Full text Commentary |
No specific funding | Interferon beta-1b | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran | N=80 |
Some concerns Details |
|
| NCT04416399 Ramakrishnan S, Lancet Respir Med, 2021 Full text Commentary Commentary |
Mixed | Budesonide | Standard care | RCT | Outpatients with suspected or confirmed COVID-19 (mild) treated by a single center in the UK | N=146 | N/A | |
| CTRI/2020/06/026222 Raman RS, J Infect Dis, 2021 Full text Commentary |
Private | Intravenous Immunoglobulin | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to four centers in India | N=100 |
Some concerns Details |
|
| IRCT20200204046369N1 Ranjbar K, BMC Infect Dis, 2021 Full text Commentary Commentary |
No specific funding | Methylprednisolone | Dexamethasone | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran | N=93 |
Some concerns Details |
|
| * Rashad A, 2021 Full text Commentary Commentary |
Not reported/unclear | Azithromycin | Standard care | RCT | Patients with confirmed COVID-19 (mild outpatients) treated at a single center in Egypt | N=305 | N/A | |
| Azithromycin | Clarithromycin | |||||||
| Clarithromycin | Standard care | |||||||
| NCT04519385 Rashad A, Scientific Reports, 2021 Full text Commentary Commentary |
Not reported/unclear | Tocilizumab | Dexamethasone | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Egypt | N=149 |
High Details |
|
| N/A Rasheed A, Le Infezioni in Medi, 2020 Full text |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with COVID-19 (severe) admitted to 3 centers in Iraq. | N=49 | N/A | |
| NCT04459247 Rastogi A, Postgrad Med J, 2020 Full text Commentary Commentary |
No specific funding | Cholecalciferol | Placebo | RCT | Patients with confirmed COVID-19 (symptomatic or asymptomatic mild) admitted to a single center in India | N=40 | N/A | |
| CTRI/2021/05/033544 Ravichandran R, medRxiv, 2021 Full text Commentary Commentary |
Not reported/unclear | Indomethacin | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India. | N=210 |
Some concerns Details |
|
| CTRI/2020/08/027225 Ravikirti R, J Pharm Pharm Sci, 2021 Full text Full text Commentary Commentary Commentary |
Mixed | Ivermectin | Placebo | RCT | Patients with COVID-19 (mild-severe) admitted to a single center in India | N=115 |
High Details |
|
| CTRI/2020/05/025209 Ray Y, medRxiv, 2020 Full text Commentary Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in India | N=80 |
High Details |
|
| NCT04420247 Rea-Neto A, Scientific Reports, 2021 Full text Commentary |
Not reported/unclear | Chloroquine/Hydroxychloroquine | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 6 centers in Brazil | N=142 |
Some concerns Details |
|
| NCT04727424 Reis G, medRxiv, 2021 Full text Commentary Commentary |
Public/non profit | Fluvoxamine | Placebo | RCT | Outpatients with confirmed COVID-19 (mild, symptomatic) treated by 11 centers in Brazil | N=1472 |
Low Details |
|
| NCT04403100 Reis G, TOGETHER, 2021 Full text Commentary Commentary |
Public/non profit | Lopinavir-Ritonavir | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated at local public health facilities in 10 cities in Brazil | N=685 |
Some concerns Details |
|
| Lopinavir-Ritonavir | Hydroxychloroquine | |||||||
| Hydroxychloroquine | Placebo | |||||||
| NCT04409262 REMDACTA, Unpublished, 2021 |
Private | Placebo | Tocilizumab | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a multiple centers in Spain, USA, Brazil and Russia. | N=640 |
Some concerns Details |
|
| ChiCTR2000029853 Ren Z, Adv Sci, 2020 Full text Commentary |
Mixed | Azvudine | Standard care | RCT | Patients with COVID-19 (mild-moderate) admitted to a single center in China | N=20 |
Some concerns Details |
|
| RBR-5vpyh4 Resende GG, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Secukinumab | Standard care | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Brazil | N=50 |
Some concerns Details |
|
| NCT04552483 Rocco PRM, Eur Respir J, 2020 Full text Commentary |
Mixed | Nitazoxanide | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated at 7 centers in Brazil | N=475 |
Some concerns Details |
|
| RBR-95yjmq Rodrigues C, Int J Antimicrob Agents, 2021 Full text Commentary |
Private | Hydroxychloroquine + Azithromycin | Placebo | RCT | Outpatients with confirmed COIVD-19 (symptomatic, mild) treated by a single center in Brazil | N=84 |
Low Details |
|
| IRCT20190810044500N7 Roostaei A, BMC Infect Dis, 2021 Full text Commentary Commentary |
Public/non profit | Levamisole | Placebo | RCT | Outpatients with COVID-19 (mild) treated at a single center in Iran | N=52 |
Some concerns Details |
|
| IRCT20200403046926N1 Roozbeh F, J Antimicrob Chemoth, 2020 Full text Commentary |
Public/non profit | Sofosbuvir-Daclatasvir | Standard care | RCT | Outpatients with COVID-19 (mild) treated at a single center in Iran | N=60 | N/A | |
| NCT04320615 Rosas I, N Engl J Med, 2021 Full text Commentary |
Mixed | Tocilizumab | Placebo | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to multiple centers across 9 countries | N=452 |
Low Details |
|
| NCT04486313 Rossignol JF, medRxiv, 2021 Full text Commentary Commentary |
Private | Nitazoxanide | Placebo | RCT | Outpatients with confirmed or suspected COVID-19 (mild, symptomatic) treated at 36 centers in Puerto Rico and USA. | N=* |
Some concerns Details |
|
| Trial NL8504 Rutgers A, SSRN, 2021 Full text Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 11 centers in the Netherlands. | N=354 |
Some concerns Details |
|
| NCT04501783 Ruzhentsova TA, SSRN, 2020 Full text Commentary Commentary |
Private | Favipiravir | Standard care | RCT | Outpatients and inpatients with confirmed COVID-19 (mild-moderate) treated at 10 centers in Russia | N=168 |
Some concerns Details |
|
| Saudi Clinical Trial Registry (SCTR): 20061006 Sabico S, Nutrients, 2021 Full text Commentary |
Mixed | Vitamin D 5000 IU | Vitamin D 1000 IU | RCT | Patients with confirmed COVID-19 (mild outpatients or hospitalised mild-moderate) admitted or treated by 2 centers in Saudi Arabia | N=73 |
Some concerns Details |
|
| IRCT20200128046294N2 Sadeghi A, J Antimicrob Chemoth, 2020 Full text Commentary |
Mixed | Sofosbuvir-Daclatasvir | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Iran | N=70 |
Some concerns Details |
|
| NCT04411667 Sakoulas G, Crit Care Expl , 2020 Full text Commentary |
Private | Intravenous Immunoglobulin | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in USA. | N=34 |
Some concerns Details |
|
| NCT04372186 Salama C, N Engl J Med, 2020 Full text Full text Commentary Commentary |
Private | Tocilizumab | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 65 centers in Brazil, Kenya, Mexico, Peru, South Africa, and USA | N=388 |
Some concerns Details |
|
| IRCT20200418047126N1 Salehzadeh F, Research Square, 2020 Full text Commentary |
Public/non profit | Colchicine | Placebo | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Iran | N=100 |
Some concerns Details |
|
| N/A Sali S, Novelty in Biomedicine, 2021 Full text |
Public/non profit | Hydroxychloroquine+Sofosbuvir | Hydroxychloroquine+Lopinavir-Ritonavir | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran | N=54 |
Some concerns Details |
|
| NCT04530370 Salman OH, Egypt J Anaesth, 2020 Full text Commentary |
Not reported/unclear | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Egypt | N=30 |
Some concerns Details |
|
| NCT04346355 Salvarani C, JAMA , 2020 Full text Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to 24 centers in Italy | N=126 |
Some concerns Details |
|
| ChiCTR2000033627 Samaha A,, Viruses, 2021 Full text Commentary |
No specific funding | Ivermectin | Standard care | RCT | Outpatients with confirmed COVID-19 (asymptomatic-mild) recruited through testing centers in Lebanon. | N=100 |
Some concerns Details |
|
| IRCT20200509047364N2 Samimagham HR, Research Square, 2021 Full text Commentary Commentary |
Public/non profit | Famotidine | Standard care | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Iran | N=20 |
Some concerns Details |
|
| NCT04489446 Santamarina MG, SSRN, 2021 Full text Commentary Commentary |
No specific funding | Sildenafil | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Chile. | N=40 | N/A | |
| NCT04357808 SARCOVID, Unpublished, 2021 |
Mixed | Sarilumab | Standard care | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Spain. | N=30 |
Low Details |
|
| NCT04357860, EU-CTR 2020-001531-27 SARICOR, Unpublished, 2021 |
Public/non profit | Sarilumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to 10 centers in Spain | N=115 |
Low Details |
|
| EU-CTR 2020-002037-15 SARTRE, Unpublished, 2021 |
Private | Sarilumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 5 centers in Spain | N=140 |
Low Details |
|
| IRCT20130812014333N145 Sayad B, J Antimicrob Chemother, 2021 Full text Commentary |
Public/non profit | Sofosbuvir/Velpatasvir | Standard care | RCT | Patients with confirmed or suspected COVID-19 (severe) admitted to a single center in Iran. | N=80 |
Some concerns Details |
|
| NCT04329611 Schwartz I, CMAJ Open, 2021 Full text Commentary |
Mixed | Hydroxychloroquine | Placebo | RCT | Outpatients with confirmed COVID-19 (mild, symptomatic) treated in the community by the public health system in Canada | N=148 |
Some concerns Details |
|
| IRCT20200511047399N1 Sedighiyan M, Authorea, 2021 Full text Commentary |
Public/non profit | Hydroxychloroquine+Omega-3 | Hydroxychloroquine | RCT | Patients with COVID-19 (unclear severity) admitted to a single center in Iran | N=39 | N/A | |
| IRCT20200415047092N1 Sekhavati E, Int J Antimicrob Age, 2020 Full text Commentary |
Public/non profit | Azithromycin | Standard care | RCT | Patients with COVID-19 confirmed (moderate-severe) admitted to a single center in Iran | N=111 |
Some concerns Details |
|
| NCT04547660 Sekine L, Eur Respir J, 2021 Full text Commentary |
Public/non profit | Convalescent plasma | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Brazil. | N=160 |
Some concerns Details |
|
| NCT04332991 Self W, JAMA, 2020 Full text Commentary Commentary |
Mixed | Hydroxychloroquine | Placebo | RCT | Patients with COVID-19 confirmed (mild-critical) admitted to 34 centers in the USA | N=479 |
Some concerns Details |
|
| NCT04392713 Shah Bukhari K H, medRxiv, 2021 Full text Commentary Commentary |
Not reported/unclear | Ivermectin | Standard care | RCT | Patients with confirmed COVID-19 (mild) admitted to a single center in Pakistan | N=100 |
High Details |
|
| IRCT20111224008507N3 Shahbaznejad L, Clin Ther, 2021 Full text Commentary |
No specific funding | Ivermectin | Standard care | RCT | Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 2 centers in Iran. | N=73 |
Some concerns Details |
|
| NCT04288102 Shi L, Signal Transduction , 2021 Full text Commentary |
Public/non profit | Human umbilical cord mesenchymal stem cell infusion | Placebo | RCT | Patients with confirmed COVID-19 (severe) admitted to two centers in China | N=101 |
Some concerns Details |
|
| JapicCTI-205238 Shinkai M, Infect Dis Ther, 2021 Full text Commentary |
Private | Favipiravir | Placebo | RCT | Patients with confirmed COVID-19 (mild/moderate) admitted to 39 centers in Japan. | N=156 |
Some concerns Details |
|
| NCT04362085; NCT04444700 Sholzberg M, medRxiv, 2021 Full text Commentary Commentary |
Public/non profit | Therapeutic Heparin | Prophylactic Heparin | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a 28 centers in Brazil, Canada, Ireland, Saudi Arabia, UAE, USA. | N=465 |
Some concerns Details |
|
| ChiCTR2000031494 Shu L, Stem Cell Res Ther, 2020 Full text Commentary |
Public/non profit | Human umbilical cord mesenchymal stem cell infusion | Standard care | RCT | Patients with COVID-19 (severe) admitted to a single center China | N=41 |
Some concerns Details |
|
| IRCT20200504047298N3 Siami Z, Int J Infect Dis, 2021 Full text Commentary |
Public/non profit | Ammonium chloride | Placebo | RCT | Outpatients and inpatients with suspected or confirmed COVID-19 admitted to or treated by a single center in Iran | N=120 |
High Details |
|
| NCT04512027; CTRI/2020/09/027833 Sigamani A, J Vaccines Vaccin, 2020 Full text Commentary |
Private | Prolectin-M | Standard care | RCT | Patients with confirmed COVID-19 (mild) admitted to a single center in India | N=10 |
Some concerns Details |
|
| NCT04463264 Silva M, medRxiv, 2021 Full text Commentary Commentary |
Private | Nitazoxanide | Placebo | RCT | Outpatients and inpatients with confirmed COVID-19 (asymptomatic or symptomatic-mild) treated by or admitted to two centers in Argentina | N=46 |
High Details |
|
| NCT04383535 Simonovich VA, N Engl J Med, 2020 Full text Commentary |
Mixed | Convalescent plasma | Placebo | RCT | Patients with confirmed COVID-19 (severe) admitted to 12 centers in Argentina | N=334 |
Some concerns Details |
|
| CTRI/2020/06/025575 Singh B(2), medRxiv, 2021 Full text Commentary Commentary |
No specific funding | Hydroxychloroquine+Ribavirin | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in India. | N=40 |
Some concerns Details |
|
| CTRI/2020/06/025575 Singh B, 2021 Full text Commentary Commentary |
No specific funding | HCQ+RBV | Standard care | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in India. | N=71 |
Some concerns Details |
|
| LPV/r+RBV | Standard care | |||||||
| HCQ+RBV | LPV/r+RBV | |||||||
| NCT04402866; EudraCT 2020-001807-18 Singh D, 2021 Full text Commentary Commentary |
Private | TD-0903 1 mg | Placebo | RCT | Patients with confirmed COVID-19 (moderate) admitted to centers in Moldova, UK and Ukraine. | N=25 |
Some concerns Details |
|
| TD-0903 1 mg | TD-0903 3 mg | |||||||
| TD-0903 1 mg | TD-0903 10 mg | |||||||
| TD-0903 3 mg | Placebo | |||||||
| TD-0903 3 mg | TD-0903 10 mg | |||||||
| TD-0903 10 mg | Placebo | |||||||
| NCT04322396, EudraCT 2020-001198-55 Sivapalan P, Eur Respir J, 2021 Full text Commentary |
Mixed | Hydroxychloroquine + Azithromycin | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 6 centers in Denmark | N=117 |
Low Details |
|
| NCT04315298 Sivapalasingam S (1), 2021 Full text Commentary Commentary |
Private | Sarilumab 400mg | Placebo | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 56 centers in the USA | N=457 |
Some concerns Details |
|
| Sarilumab 200mg | Placebo | |||||||
| Sarilumab 400mg | Sarilumab 200mg | |||||||
| NCT04315298 Sivapalasingam S (2), 2021 Full text Commentary Commentary |
Private | Sarilumab 400mg | Placebo | RCT | Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 56 centers in the USA | N=1330 |
Some concerns Details |
|
| Sarilumab 200mg | Placebo | |||||||
| Sarilumab 400mg | Sarilumab 200mg | |||||||
| NCT04308668 Skipper CP, Ann Intern Med, 2020 Full text Commentary |
Private | Hydroxychloroquine | Placebo | RCT | Outpatients with suspected or confirmed COVID-19 (symptomatic, mild) with high-risk exposure within 4 days of symptom onset | N=491 |
Some concerns Details |
|
| NCT04715295 Sobngwi E, medRxiv, 2021 Full text Commentary Commentary |
Public/non profit | Doxycycline | Hydroxychloroquine + Azithromycin | RCT | Outpatients with confirmed COVID-19 (asymptomatic and mild) treated at a single center in Cameroon. | N=194 |
Some concerns Details |
|
| CTRI/2020/05/025369 Soin AS, Lancet Respir Med, 2021 Full text Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 12 centers in India | N=180 |
Some concerns Details |
|
| NCT04341038; EudraCT 2020-001445-39 Solanich X, Front Med, 2021 Full text Commentary Commentary |
Public/non profit | Methylprednisolone pulse+Tacrolimus | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Spain | N=55 |
Some concerns Details |
|
| IRCT20200318046812N1 Solaymani-Dodaran M, Int Immunopharmacol, 2021 Full text Commentary |
Public/non profit | Favipiravir | Lopinavir-Ritonavir | RCT | Patients with suspected or confirmed COVID-19 (severe) admitted to 20 centers in Iran | N=424 |
Some concerns Details |
|
| NCT04330586 Song JY, J Clin Med, 2021 Full text Commentary |
Mixed | Ciclesonide | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to 6 centers in South Korea. | N=* |
High Details |
|
| NCT04292730 Spinner CD, JAMA, 2020 Full text Commentary |
Private | Remdesivir 5 days | Standard care | RCT | Patients with COVID-19 (mild-severe) admitted to 105 centers in the USA, Europe and Asia | N=596 |
Some concerns Details |
|
| Remdesivir 10 days | Standard care | |||||||
| Remdesivir 5 days | Remdesivir 10 days | |||||||
| NCT04356937 Stone JH, N Engl J Med, 2020 Full text Commentary |
Private | Tocilizumab | Placebo | RCT | Patients with COVID-19 (mild-severe) admitted to seven centers in USA | N=243 |
Low Details |
|
| NCT04579393 Strich JR, Clin Infect Dis, 2021 Full text Commentary Commentary |
Mixed | Fostamatinib | Placebo | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 2 centers in USA. | N=59 |
Low Details |
|
| IRCT20151227025726N20 Tabarsi P, Int Immunopharmacol, 2020 Full text Commentary |
Public/non profit | Intravenous Immunoglobulin | Standard care | RCT | Patients with COVID-19 (severe) admitted to a single center in Iran | N=84 |
Some concerns Details |
|
| IRCT20081027001411N4 Talaschian M, Research Square, 2021 Full text Commentary Commentary |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran | N=40 |
High Details |
|
| ChiCTR2000029868 Tang W, BMJ, 2020 Full text Commentary Commentary |
Mixed | Hydroxychloroquine | Standard care | RCT | Patients with COVID-19 (mild, moderate and severe) admitted to 16 centers in China | N=150 |
Some concerns Details |
|
| NCT04273321 Tang X, Respiration, 2021 Full text Commentary |
Public/non profit | Methylprednisolone | Placebo | RCT | Patients with confirmed COVID-19 (moderate/severe) admitted to 7 centers in China. | N=86 |
Some concerns Details |
|
| NCT04322682 Tardif JC, Lancet Respir Med, 2021 Full text Commentary Commentary |
Mixed | Colchicine | Placebo | RCT | Outpatients with suspected or confirmed COVID-19 (mild) at multiple centers in Brazil, Canada, Greece, South Africa, Spain, USA | N=* |
Details |
|
| NCT04351152 Temesgen Z, medRxiv, 2021 Full text Commentary Commentary |
Private | Lenzilumab | Placebo | RCT | Patients with confirmed COVID-19 (moderate to severe) admitted to 29 centers in Brazil and USA. | N=520 |
Some concerns Details |
|
| CTRI/2020/04/024729 Thakar A, Indian J Med Res, 2021 Full text Commentary Commentary |
Public/non profit | Chloroquine | Standard care | RCT | Patients with confirmed COVID-19 (asymptomatic-mild) admitted to a single center in India | N=60 |
Some concerns Details |
|
| NCT04342728 Thomas S, COVID A to Z, 2021 Full text Commentary Commentary |
Not reported/unclear | Vitamin C | Standard care | RCT | Outpatients with confirmed COVID-19 (asymptomatic-mild) treated by multiple centers in the US. | N=214 |
Some concerns Details |
|
| Vitamin C | Zinc | |||||||
| Vitamin C | Vitamin C+Zinc | |||||||
| Zinc | Vitamin C+Zinc | |||||||
| Zinc | Standard care | |||||||
| Vitamin C+Zinc | Standard care | |||||||
| NCT04332094, EudraCT 2020-001442-19 TOCOVID, Unpublished, 2021 |
Public/non profit | Standard care | Tocilizumab | RCT | Patients with confirmed COVID-19(mild-moderate) admitted to multiple centers in Spain. | N=270 |
Low Details |
|
| IRCT20151227025726N24 Tolouian R, J Investig Med, 2021 Full text Commentary Commentary |
No specific funding | Bromhexine hydrochloride | Standard care | RCT | Patients with confirmed COVID-19 pneumonia (symptomatic, unclear severity) admitted to a single center in Iran | N=111 |
High Details |
|
| NCT04327401 Tomazini BM, JAMA, 2020 Full text Commentary |
Mixed | Dexamethasone | Standard care | RCT | Patients with suspected or confirmed COVID-19 (critical) admitted to 41 centers in Brazil | N=299 |
Some concerns Details |
|
| NCT04452435 Tornling G, SSRN, 2021 Full text Full text Commentary Commentary |
Mixed | Compound 21 | Placebo | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to 8 centers in India | N=106 |
Some concerns Details |
|
| CTRI/2020/05/025114 Udwadia Z, Int J Infect Dis, 2020 Full text Commentary |
Private | Favipiravir | Standard care | RCT | Patients with confirmed COVID-19 (mild/moderate) admitted to 7 centers in India | N=150 |
Some concerns Details |
|
| NCT04369742 Ulrich RJ, Open Forum Infect Di, 2020 Full text Commentary |
Public/non profit | Hydroxychloroquine | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 5 centers in USA | N=128 |
Some concerns Details |
|
| NCT04324073 Unpublished, 2021 |
Public/non profit | Sarilumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (severe-critical) admitted to multiple centers in France. | N=* |
Some concerns Details |
|
| NCT04529525 Vallejos J, BMC Infect Dis, 2021 Full text Commentary |
No specific funding | Ivermectin | Placebo | RCT | Outpatients with confirmed COVID-19 (asymptomatic-mild) treated by a single center in Argentina | N=501 |
Low Details |
|
| NCT04403685 Veiga VC, BMJ, 2021 Full text Commentary Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 9 centers in Brazil | N=129 |
Some concerns Details |
|
| NCT04325061 Villar J, Unpublished, 2020 |
Public/non profit | Dexamethasone | Standard care | RCT | Patients with confirmed COVID-19 (critical) admitted 14 centers in Spain | N=19 |
Low Details |
|
| NCT04333420 Vlaar APJ, Lancet Rheumatol, 2020 Full text Commentary |
Private | IFX-1 | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to three centers | N=30 |
Some concerns Details |
|
| ChiCTR2000029765 Wang D, Front Med, 2021 Full text Full text Commentary |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in China | N=65 |
Some concerns Details |
|
| ChiCTR2000030058 Wang M, Clin Infect Dis, 2020 Full text Commentary |
Public/non profit | Leflunomide + Interferon alpha2a | Interferon alpha2a | RCT | Patients with confirmed COVID-19 (mild) admitted to a single center China | N=50 |
Some concerns Details |
|
| NCT04257656 Wang Y, Lancet, 2020 Full text Commentary |
Mixed | Remdesivir | Placebo | RCT | Patients with confirmed COVID-19 (severe) admitted to 10 centers in China | N=237 |
Some concerns Details |
|
| NCT04425629 Weinreich D (2), medRxiv, 2021 Full text Commentary Commentary |
Mixed | Casirivimab+Imdevimab (REGN-COV2) 1200mg | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated at 82 centers in Mexico and the USA. | N=1678 |
Some concerns Details |
|
| NCT04425629 Weinreich D, medRxiv, 2021 Full text Commentary Commentary |
Mixed | Casirivimab+Imdevimab (REGN-COV2) 2400mg | Placebo | RCT | Outpatients with confirmed COVID-19 (mild) treated in 82 centers in Mexico and the USA. | N=3029 |
Some concerns Details |
|
| N/A Winchester S, J Infect, 2021 Full text 00251-6/fulltext Commentary |
Private | Nitric Oxide Nasal Spray | Placebo | RCT | Patients with confirmed COVID-19 (mild) isolated and treated at a single center in the UK. | N=80 |
Some concerns Details |
|
| ChiCTR2000030001 Wu X, Engineering, 2020 Full text Commentary |
Public/non profit | Triazavirin | Placebo | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 10 centers in China | N=52 |
Some concerns Details |
|
| IRCT20200328046885N1 Yadollahzadeh M, Research square , 2021 Full text Commentary Commentary |
Public/non profit | Sofosbuvir-Daclatasvir | Lopinavir-Ritonavir | RCT | Patients with CT-scan-confirmed COVID-19 (moderate-severe) admitted to a single center in Iran | N=112 |
High Details |
|
| DRKS00022203 Yakoot M, SSRN, 2020 Full text Commentary Commentary |
Private | Sofosbuvir-Daclatasvir | Standard care | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Egypt | N=89 |
Some concerns Details |
|
| N/A Yethindra V, Int J Res Pharm Sci, 2020 Full text Commentary |
No specific funding | Umifenovir | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in Kyrgyzstan | N=30 |
Some concerns Details |
|
| NCT04311697 Youssef J, SSRN, 2021 Full text Full text Commentary |
Mixed | Aviptadil | Placebo | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 10 centers in the USA. | N=203 |
Some concerns Details |
|
| ISRCTN86534580; EudraCT 2020-001209-22 Yu LM, Lancet, 2021 Full text Full text Commentary Commentary Commentary |
Public/non profit | Budesonide | Standard care | RCT | Outpatients with suspected or confirmed COVID-19 (symptomatic-mild) treated by multiple centers in the UK | N=1073 |
Some concerns Details |
|
| ChiCTR2000029431 Yuan X, medRxiv, 2020 Full text Commentary |
Public/non profit | Tc-MDP | Standard care | RCT | Patients with confirmed COVID-19 (unclear severity) admitted to 2 centers in China | N=21 | N/A | |
| NCT04252885 Yueping L, 2020 Full text Commentary |
Public/non profit | Lopinavir-Ritonavir | Standard care | RCT | Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in China. | N=86 |
Some concerns Details |
|
| Lopinavir-Ritonavir | Umifenovir | |||||||
| Lopinavir-Ritonavir | Umifenovir | |||||||
| IRCT20200505047318N1 Zarehoseinzade E , Med J Islam Repub Ir, 2021 Full text Commentary |
Public/non profit | Finasteride | Standard care | RCT | Patients with suspected or confirmed COVID-19 (unclear severity) admitted to a single center in Iran | N=80 |
Some concerns Details |
|
| NCT04264533 Zhang J, Ann. Intensive Care, 2021 Full text Commentary |
Public/non profit | Vitamin C | Placebo | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 3 centers in China | N=56 |
Some concerns Details |
|
| ChiCTR2000030894, NCT04310228 Zhao H, Biomed Pharmacother, 2020 Full text Commentary |
Public/non profit | Favipiravir | Favipiravir+Tocilizumab | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 4 centers in China | N=26 |
Some concerns Details |
|
| Tocilizumab | Favipiravir+Tocilizumab | |||||||
| Favipiravir | Tocilizumab | |||||||
| NCT04333589 Zhao H, Int Immunopharmacol, 2021 Full text Commentary |
Public/non profit | Favipiravir | Standard care | RCT | Outpatients whith confirmed recurrent COVID-19 (mild),isolated and treated by 5 centres in China. | N=55 |
Some concerns Details |
|
| ChiCTR2000029496 Zheng F, 2020 Full text Commentary |
Public/non profit | Novaferon+LPV/r | Lopinavir-Ritonavir | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in China. | N=89 |
Some concerns Details |
|
| Novaferon+LPV/r | Novaferon | |||||||
| Novaferon | Lopinavir-Ritonavir | |||||||
| ChiCTR2000029851 Zhong M, medRxiv, 2020 Full text Commentary |
Private | alfa-Lipoic acid | Placebo | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to 1 center in China. | N=17 |
Some concerns Details |
|
